hNPC01 / Hopstem Biotech - LARVOL DELTA

Phase IIa Clinical Study of Human Neural Precursor Cell (hNPC) Transplantation for Ischemic Brain Injury ——A Phase IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of hNPC01 Injection Derived from Human Induced Pluripotent Stem Cells in Improving Hemiplegic Sequelae of Ischemic Stroke (ChiCTR) - P2 | N=21 | Not yet recruiting | Sponsor: Neurosurgery Department of Seventh Medical Center, Senior Department of Neurosurgery, the First Medical Center of PLA Gene; PLA General Hospital

New P2 trial • Cardiovascular • CNS Disorders • Ischemic stroke • Transplantation • Vascular Neurology

hNPC01-ISCHEMIC: Clinical Trial of Human Neural Precursor Cell (hNPC) Transplantation for Ischemic Brain Injury(——A Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of hNPC01 Injection Derived from Human Induced Pluripotent Stem Cells in Improving Hemiplegic Sequelae of Ischemic Stroke)(Phase I) (ChiCTR) - P1 | N=9 | Completed | Sponsor: Neurosurgery Department of Seventh Medical Center, Senior Department of Neurosurgery, the First Medical Center of PLA General Hospital; PLA General Ho

New P1 trial • Cardiovascular • CNS Disorders • Ischemic stroke • Transplantation • Vascular Neurology

The Preclinical and First-in-Human Study of iPSC-Derived Human Forebrain Neural Progenitor Cell Injection-hNPC01 in Treating Chronic Ischemic Stroke (ASGCT 2024) - "The current observation of first dose cohorts showed good safety and tolerance of hNPC01, as well as sign of motor function improvement in volunteer subjects with ischemic stroke onset 17 to 40 months prior to the enrollment. It is expected that the 12 month safety observation and exploration of evaluation tools will provide more valuable information for the future development of iPSC cell therapy for stroke or traumatic brain injury caused brain injury patients with chronic symptoms."

Late-breaking abstract • P1 data • Preclinical • Cardiovascular • CNS Disorders • Ischemic stroke • Oncology • Vascular Neurology

The Preclinical and First-in-Human Study of iPSC-Derived Human Forebrain Neural Progenitor Cell Injection-hNPC01 in Treating Chronic Ischemic Stroke (ASGCT 2024) - "The current observation of first dose cohorts showed good safety and tolerance of hNPC01, as well as sign of motor function improvement in volunteer subjects with ischemic stroke onset 17 to 40 months prior to the enrollment. It is expected that the 12 month safety observation and exploration of evaluation tools will provide more valuable information for the future development of iPSC cell therapy for stroke or traumatic brain injury caused brain injury patients with chronic symptoms."

P1 data • Preclinical • Cardiovascular • CNS Disorders • Ischemic stroke • Oncology • Vascular Neurology

A Safety and Tolerability Study of Human Forebrain Neural Progenitor Cells Injection (hNPC01) in Subjects With Chronic Ischemic Stroke (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: Hopstem Biotechnology Inc.

New P1 trial • Cardiovascular • Ischemic stroke